PhysioCue is a digital health and therapy device development company that has developed the thermal neurostimulation technology for a non-invasive hypertension therapy device and a migraine and headache therapy device and migraine and headache pain monitoring mobile application. PhysioCue's therapy devices are efficient, safe, easy to use, and has none of the side effects associated with antihypertensive drugs and migraine headache drugs.
PhysioCue has manufactured hypertension therapy and migraine and headache therapy devices; we've delivered devices to our potential partners and users. We've received positive feedback from many people who have tried and liked our devices. PhyaioCue also launched our Migraine pain monitoring mobile app: MigraineCue. MigraineCue is able to monitor an individual's migraines and headaches daily.
We do not intend to manufacture, distribute, or sell our devices. Instead, our go-to-market strategy uses strategic regional partnerships to accomplish these steps. We are having a strategic partnership and licensing discussions with major medical suppliers, retail distributors, and health insurers in the DNR Corp. in Indonesia, Saudi Arabia, and China.
Problem or Opportunity
Drugs are expensive and can have severe side-effects that cause many patients to seek alternative treatments—or none at all. PhysioCue therapy devices are non-invasive, with no pain, immediate effect, safe, easy to use, and have none of the side effects associated with drugs. PhysioCue therapy devices are all; non-invasive, no pain, no side-effect, immediate effect, cost-effective, easy to use, and user’s friendly device. On the other hand, competitors require surgical implant or limited efficacy of the treatment effect.
Solution (product or service)
The Hypertension and Migraine/headache device market are very large globally and very important globally, especially during these times of duress where many people are at home. PhysioCue devices can help people and save lives.
Large pharmaceutical companies, including Pfizer, Merck, AstraZeneca, Novartis, Bristol Myers Squibb, Aventis, GSK and Bayer dominate the market for hypertension and migraine and headache treatment with various drugs but drugs are expensive, averaging more than $150 per month, and can have severe side-effects that cause many patients to seek alternative treatments—or none at all. “Medical therapy devices” include Resperate (www.resperate.com), a biofeedback system that trains people to breathe properly, reducing their high blood pressure over 8 weeks. CVRx (www.cvrx.com) has a surgically implanted device, this solution is invasive, prohibitively expensive, and only appeals to Stage 3 hypertensives, which is about 3% of the market.
Advantages or differentiators
PhysioCue therapy devices are all; non-invasive, with no pain, no side-effect, immediate effect, cost-effective, easy to use, and user’s friendly device. On the other hand, competitors require a surgical implant or limited efficacy of the treatment effect.
Money will be spent on
Use of Funds:
Certification for UL, CE, FDA 510 (K) Approval, Additional Clinical trials
Dedicated Sales & Marketing, Develop EU & Asia distribution channel
Independent database & software interface / Migraine Mobile App / BP Monitoring App
Final Stage R&D for Model Q3 & Q4
Legal expenses relating to additional IP & Licensing
Complete mass production capabilities & Operations Expenses
Offer for investor
The Hypertension and Migraine/headache device market are very large and very important globally, PhysioCue received the $3.5M investment from multination. Tested and received excellent feedback from users. PhysioCue has a great team with excellent medical advisory board. Active discussion with multiple global firms from partnerships.